Literature DB >> 20121731

Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients.

R L Heilman1, Y Devarapalli, H A Chakkera, K L Mekeel, A A Moss, D C Mulligan, M J Mazur, K Hamawi, J W Williams, K S Reddy.   

Abstract

Our aim was to study the impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy (IF/TA) on a 1-year protocol biopsy in patients on rapid steroid withdrawal (RSW). A total of 256 patients were classified based on protocol biopsy findings at months 1 or 4. Group 1 is 172 patients with no inflammation, group 2 is 50 patients with subclinical inflammation (SCI), group 3 is 19 patients with subclinical acute rejection (SAR) and group 4 is 15 patients with clinical acute rejection (CAR). On the 1-year biopsy, more patients in group 2 (SCI) (34%, p = 0.004) and group 3 (SAR) (53%, p = 0.0002), had an IF/TA score > 2 compared to group 1 (control) (15%). IF/TA was not increased in group 4 (CAR) (20%). The percent with IF/TA score > 2 and interstitial inflammation (Banff i score > 0) was higher in group 2 (16%, p = 0.004) and group 3 (37%, p < 0.0001) compared to group 1 (3%). In a multivariate analysis, patients in groups 2 or 3 had a higher risk of IF/TA score > 2 on the 1-year biopsy (OR 6.62, 95% CI 2.68-16.3). We conclude that SCI and SAR increase the risk of developing IF/TA in patient on RSW.

Entities:  

Mesh:

Year:  2010        PMID: 20121731     DOI: 10.1111/j.1600-6143.2009.02966.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  34 in total

1.  Transplantation: Biomarkers in transplantation—the devil is in the detail.

Authors:  Michael Abecassis; Bruce Kaplan
Journal:  Nat Rev Nephrol       Date:  2015-01-27       Impact factor: 28.314

2.  Transplantation: Utilizing the transcriptome to predict allograft fibrosis.

Authors:  Adyr Moss; Bruce Kaplan
Journal:  Nat Rev Nephrol       Date:  2016-09-19       Impact factor: 28.314

3.  Progression of Interstitial Fibrosis during the First Year after Deceased Donor Kidney Transplantation among Patients with and without Delayed Graft Function.

Authors:  Raymond L Heilman; Maxwell L Smith; Byron H Smith; Ibrahim Qaqish; Hasan Khamash; Andrew L Singer; Bruce Kaplan; Kunam S Reddy
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-24       Impact factor: 8.237

Review 4.  Allograft rejection and tubulointerstitial fibrosis in human kidney allografts: interrogation by urinary cell mRNA profiling.

Authors:  Thangamani Muthukumar; John R Lee; Darshana M Dadhania; Ruchuang Ding; Vijay K Sharma; Joseph E Schwartz; Manikkam Suthanthiran
Journal:  Transplant Rev (Orlando)       Date:  2014-05-27       Impact factor: 3.943

5.  Early subclinical rejection treated with low dose i.v. steroids is not associated to graft survival impairment: 13-years' experience at a single center.

Authors:  Paolo Gigliotti; Danilo Lofaro; Francesca Leone; Teresa Papalia; Massimino Senatore; Rosita Greco; Anna Perri; Donatella Vizza; Simona Lupinacci; Giuseppina Toteda; Antonella La Russa; Roberto De Stefano; Francesco Romeo; Renzo Bonofiglio
Journal:  J Nephrol       Date:  2015-05-13       Impact factor: 3.902

6.  Changes in Urinary Microbiome Populations Correlate in Kidney Transplants With Interstitial Fibrosis and Tubular Atrophy Documented in Early Surveillance Biopsies.

Authors:  B D Modena; R Milam; F Harrison; J A Cheeseman; M M Abecassis; J J Friedewald; A D Kirk; D R Salomon
Journal:  Am J Transplant       Date:  2016-10-11       Impact factor: 8.086

Review 7.  Kidney Fibrosis: Origins and Interventions.

Authors:  Thomas Vanhove; Roel Goldschmeding; Dirk Kuypers
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

8.  Orthogonal Comparison of Molecular Signatures of Kidney Transplants With Subclinical and Clinical Acute Rejection: Equivalent Performance Is Agnostic to Both Technology and Platform.

Authors:  S M Kurian; E Velazquez; R Thompson; T Whisenant; S Rose; N Riley; F Harrison; T Gelbart; J J Friedewald; J Charette; S Brietigam; J Peysakhovich; M R First; M M Abecassis; D R Salomon
Journal:  Am J Transplant       Date:  2017-04-03       Impact factor: 8.086

9.  Gene Expression in Biopsies of Acute Rejection and Interstitial Fibrosis/Tubular Atrophy Reveals Highly Shared Mechanisms That Correlate With Worse Long-Term Outcomes.

Authors:  B D Modena; S M Kurian; L W Gaber; J Waalen; A I Su; T Gelbart; T S Mondala; S R Head; S Papp; R Heilman; J J Friedewald; S M Flechner; C L Marsh; R S Sung; H Shidban; L Chan; M M Abecassis; D R Salomon
Journal:  Am J Transplant       Date:  2016-03-15       Impact factor: 8.086

10.  Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants.

Authors:  S Chandran; Q Tang; M Sarwal; Z G Laszik; A L Putnam; K Lee; J Leung; V Nguyen; T Sigdel; E C Tavares; J Y C Yang; M Hellerstein; M Fitch; J A Bluestone; F Vincenti
Journal:  Am J Transplant       Date:  2017-08-14       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.